...
首页> 外文期刊>American Journal of Physiology >A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation.
【24h】

A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation.

机译:单核细胞趋化蛋白-1在血管内皮细胞瘤增殖中的关键血管生成作用。

获取原文
获取原文并翻译 | 示例

摘要

Angiomatous lesions are common in infants and children. Hemangioendotheliomas (HE) represent one type of these lesions. Endothelial cell proliferation and the development of vascular/blood cell-filled spaces are inherent in the growth of HE. Therefore, understanding mechanisms that regulate the proliferation of these lesions should provide key insight into mechanisms regulating angiogenesis. A murine model was used to test the significance of monocyte chemoattractant protein (MCP)-1 in HE proliferation. EOMA cells, a cell line derived from a spontaneously arising murine HE, generate these lesions with 100% efficiency when injected subcutaneously into syngeneic mice. MCP-1 produced by EOMA cells recruit macrophages, which were shown to induce angiogenic behavior in EOMA cells by stimulating transwell migration and inducing sprout formation on type I collagen gels. When EOMA cells were injected into MCP-1(-/-) mice, only 50% of the mice developed tumors, presumably because the low levels of MCP-1 expressed by the injected EOMA cells were enough to overcome any host deficits of this chemokine. When EOMA cells were coinjected with a neutralizing antibody to MCP-1, tumors failed to develop in any of the treated mice, including syngeneic 129P3, C57Bl/6 (wild type), and MCP-1(-/-). These results present the first evidence that MCP-1 is required for HE proliferation and may promote the growth of these lesions by stimulating angiogenic behavior of endothelial cells. This study has produced the first in vivo evidence of a complete response for any neoplasm, specifically a vascular proliferative lesion, to anti-MCP-1 therapy in animals with intact immune systems.
机译:血管瘤性病变常见于婴儿和儿童。血管内皮瘤(HE)代表了这些病变的一种。内皮细胞的增殖和血管/血细胞填充空间的发育是HE生长所固有的。因此,了解调节这些病变增殖的机制应提供对调节血管生成的机制的关键见解。使用鼠模型测试单核细胞趋化蛋白(MCP)-1在HE增殖中的重要性。 EOMA细胞是一种自发产生的鼠类HE衍生的细胞系,当皮下注射到同系小鼠中时,能以100%的效率产生这些病变。由EOMA细胞产生的MCP-1募集巨噬细胞,这些巨噬细胞通过刺激跨孔迁移并诱导I型胶原蛋白凝胶上的新芽形成,从而诱导EOMA细胞中的血管生成行为。当将EOMA细胞注射到MCP-1(-/-)小鼠中时,只有50%的小鼠发生了肿瘤,这大概是因为被注射的EOMA细胞表达的MCP-1的低水平足以克服这种趋化因子的宿主缺陷。当EOMA细胞与抗MCP-1的中和抗体共同注射时,肿瘤在任何治疗的小鼠中均未发育,包括同基因129P3,C57Bl / 6(野生型)和MCP-1(-/-)。这些结果提供了第一个证据,表明MCP-1是HE增殖所必需的,并且可能通过刺激内皮细胞的血管生成行为来促进这些病变的生长。这项研究产生了第一个体内证据,证明具有完整免疫系统的动物中的任何肿瘤,特别是血管增生性病变,都对抗MCP-1治疗具有完全反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号